

Molecular Docking, Scaffolding, And Antioxidant Assessment of C2-Functionalized Benzimidazoles: A Comprehensive Review

Sunil Kumar^{1*}, Rameshwar Singh²

¹M. Pharm Scholar, Acharya Narendra Dev College of Pharmacy, Gonda, Uttar Pradesh, India

²Assistant Professor, Acharya Narendra Dev College of Pharmacy, Gonda, Uttar Pradesh, India

Date of Submission: 04-05-2026

Date of Acceptance: 13-05-2026

Abstract: Benzimidazole derivatives are attractive templates for designing multifunctional small molecules capable of engaging both enzymatic and oxidative stress pathways. This review evaluates a series of C2-substituted benzimidazoles (B1–B12) designed to probe how electronic and structural variation at the C2 position influences molecular recognition and antioxidant behavior. In silico docking against oxidative stress-related protein targets revealed that derivatives bearing strong electron-withdrawing aryl groups (e.g., 4-trifluoromethyl) achieved superior binding energies, reaching -10.2 kcal/mol. Conversely, antioxidant capacity assays (DPPH and ABTS) demonstrated that electron-donating aryl derivatives (4-methoxy and 4-methyl) displayed the lowest IC₅₀ values (7.5–11.2 μ M). This synthesis demonstrates that judicious C2-functionalization enables the simultaneous optimization of target binding and radical scavenging, positioning benzimidazole as a versatile platform for multifunctional therapeutics.

I. Introduction

The discovery of therapeutic agents capable of addressing complex pathophysiological conditions remains a central objective in contemporary medicinal chemistry. Among the diverse chemical scaffolds employed in rational drug design, benzimidazoles have emerged as privileged heterocyclic architectures demonstrating remarkable versatility in pharmaceutical applications. The benzimidazole nucleus, consisting of a fused bicyclic system combining a benzene ring with an imidazole moiety, possesses structural characteristics that render it isosteric to naturally occurring nucleotides.

Chronic diseases such as cancer, diabetes, neurodegeneration, and cardiovascular disorders are increasingly recognized as multifactorial conditions in which dysregulated signaling pathways coexist with sustained overproduction of reactive oxygen species (ROS). This complexity has fueled interest in multifunctional scaffolds that can engage

specific molecular targets while also providing intrinsic antioxidant protection.

Within the benzimidazole pharmacophore, the C2-position represents a particularly strategic site for chemical modification to enhance target affinity while maintaining favorable drug-like characteristics.

II. Benzimidazole as a Privileged Pharmacophore

Benzimidazole is recognized as a privileged structural motif because it appears recurrently in bioactive molecules with diverse pharmacological profiles. Its bicyclic framework mimics the geometry and hydrogen-bonding patterns of purine bases, allowing it to engage nucleic-acid-associated targets and purine-recognizing enzymes through competitive binding modes. Numerous marketed drugs, such as omeprazole (proton pump inhibitor), albendazole (anthelmintic), and mebendazole, utilize the benzimidazole core, illustrating its versatility across various therapeutic indications.

III. Antioxidant Activity and Oxidative Stress

Oxidative stress, defined as an imbalance between the production of reactive oxygen species (ROS) and the capacity of endogenous antioxidant systems, plays a central role in the initiation and progression of many chronic disorders. Superoxide anion, hydroxyl radical, hydrogen peroxide, and peroxynitrite can damage lipids, proteins, and nucleic acids, leading to impaired cellular function and cell death.

Nitrogen heterocycles, including benzimidazoles, are particularly intriguing because their electron-rich ring systems can be tailored to promote radical scavenging. The radical scavenging mechanisms operative in heterocyclic compounds proceed

through multiple pathways, including:

- **Hydrogen Atom Transfer (HAT):** The antioxidant donates a hydrogen atom to a radical species.
- **Single-Electron Transfer (SET):** Followed by proton transfer (SET-PT), or sequential proton loss electron transfer (SPLET).

IV. Computational Chemistry and Molecular Docking

Table 1: Docking Scores and Physicochemical Characteristics

Code	C2 Substituent	Binding Energy (kcal/mol)	LogP	Yield (%)
B1	Phenyl	-8.5	2.5	82
B2	4-Nitrophenyl (EWG)	-9.8	2.1	74
Code	C2 Substituent	Binding Energy (kcal/mol)	LogP	Yield (%)
B3	4-Chlorophenyl (EWG)	-9.5	2.3	79
B4	4-Methoxyphenyl (EDG)	-8.8	3.2	85
B5	4-Methylphenyl (EDG)	-8.4	3.4	87
B8	Pyridin-2-yl	-9.1	-	-
B12	4-Trifluoromethylphenyl	-10.2	-	-

V. Synthetic Methodologies

The classical synthesis of 2-substituted benzimidazoles is rooted in the reaction of o-phenylenediamines with carboxylic acids under dehydrating conditions (Phillips–Ladenburg method). Under refluxing conditions in the presence of an acid catalyst like glacial acetic acid, the carboxylic acid becomes activated for nucleophilic attack by the amino groups. The reaction proceeds through an amide linkage, followed by intramolecular cyclization and oxidative aromatization to afford the fully aromatic benzimidazole system.

VI. Spectroscopic Characterization

Structural confirmation of the synthesized derivatives is typically achieved through FT-IR, ¹H NMR, ¹³C NMR, and Mass Spectrometry. Characteristic signals include:

- **FT-IR:** N–H stretching bands at 3215–3388 cm⁻¹ and C=N stretching at 1608–1642 cm⁻¹.
- **¹H NMR:** Imidazole NH protons observed as downfield singlets between δ 10.62–

The integration of computational chemistry methodologies with synthetic chemistry has fundamentally transformed drug discovery. Molecular docking techniques facilitate the prediction of ligand-receptor binding modes and affinities prior to synthesis. In this investigation, a library of twelve C2-substituted benzimidazole derivatives (B1–B12) was analyzed using AutoDock Vina.

12.75 ppm.

- **¹³C NMR:** C=N carbon resonance typically appearing at δ 151.2–158.6 ppm.

VII. ADMET Assessment

Drug development requires that leads demonstrate acceptable pharmacokinetic (ADMET) profiles. All studied C2-substituted benzimidazole derivatives complied with Lipinski's rule of five (zero violations), suggesting favorable oral bioavailability. Predicted human intestinal absorption (HIA) ranged from 80.5% to 91.8%. Toxicity predictions indicated low risk for hERG inhibition and hepatotoxicity for the majority of the compounds.

VIII. Radical Scavenging Evaluation

The antioxidant potential was quantified using DPPH and ABTS assays. Compounds bearing electron-donating substituents (EDGs) like B4 (4-methoxy) and B5 (4-methyl) exhibited superior activity compared to those with electron-withdrawing groups (EWGs).

Table 2: Antioxidant Activity (IC₅₀ Values)

Compound	DPPH IC ₅₀ (μM)	ABTS IC ₅₀ (μM)
B4	9.8	7.5
B5	11.2	9.1
B1	22.4	20.3
B2	41.8	38.5
Standard (Ascorbic Acid)	~8.5	~6.8

IX. Structure-Activity Relationship (SAR) Insights

A systematic correlation exists between structural features and observed activity. Electron-donating groups increase electron density on the heterocyclic ring, facilitating hydrogen atom transfer (HAT) and stabilizing resulting radicals through resonance. Conversely, electron-withdrawing groups like -NO₂ or -CF₃ enhance binding affinity in docking studies due to stronger electrostatic interactions but reduce radical scavenging efficiency by decreasing electron availability.

X. Discussion

The study highlights a critical divergence between optimal features for protein binding versus antioxidant performance. While B12 (trifluoromethyl) achieved the best docking score, B4 (methoxy) proved to be the most potent antioxidant. This indicates that medicinal chemists must balance these electronic effects depending on whether the primary goal is enzyme inhibition or direct radical neutralization. The high correlation ($R^2 \approx 0.93$) between DPPH and ABTS assays validates the dual-mechanism scavenging potential of this scaffold.

XI. Conclusion

Systematic C2 functionalization of the benzimidazole core offers an effective strategy to modulate both protein-binding affinity and antioxidant potency. The study identifies B4 and B5 as promising lead candidates for developing multifunctional agents addressing oxidative stress-driven pathologies. All synthesized compounds fall within a favorable drug-like physicochemical window, establishing a clear path for further biological evaluation and lead optimization.

References

- [1]. Dounay AB, Curran TT. Imidazoles and Benzimidazoles. *Heterocyclic Chemistry in Drug Discovery*. 2013:333.
- [2]. Alghamdi SS, et al. Imidazole as a promising medicinal scaffold: current status and future direction. *Drug Design, Development and Therapy*. 2021:3289-312.
- [3]. Veerasamy R, et al. Structure-activity relationship analysis of benzimidazoles as emerging anti-inflammatory agents. *Pharmaceuticals*. 2021;14(7):663.
- [4]. Marinescu M, Zalaru C. Benzimidazole-Pyrimidine Hybrids: Synthesis and Medicinal Properties. *Pharmaceuticals*. 2025;18(8):1225.
- [5]. Luo X, et al. Application of Carboxylic Acid Bioisosteres in Drug Structure Optimization. *Eur. J. Med. Chem*. 2025:118104.
- [6]. Waszkowycz B. Towards improving compound selection in structure-based virtual screening. *Drug Discov Today*. 2008;13:219-26.
- [7]. Wang E, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA. *Chem Rev*. 2019;119:9478-508.
- [8]. Hou T, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. *J Chem Inf Model*. 2011;51:69-82.
- [9]. Houldsworth A. Role of oxidative stress in neurodegenerative disorders. *Brain Communications*. 2024;6:fcad356.
- [10]. Baliyan S, et al. Determination of antioxidants by DPPH radical scavenging activity. *Molecules*. 2022;27:1326.
- [11]. Alam MN, et al. Review on in vivo and in vitro methods evaluation of antioxidant activity. *Saudi Pharm J*. 2013;21:143-52.
- [12]. Klein E, Lukes V. DFT/B3LYP study of the substituent effect on phenols antioxidant action. *J Phys Chem A*. 2006;110:12312-20.
- [13]. Charlton NC, et al. Structural features of

- small molecule antioxidants. *Molecules*. 2023;28:1057.
- [14]. Tiwana JK, et al. Involvement of ROS in chronic diseases. *Scripta Medica*. 2024;55:199-217.
- [15]. Gaba M, Mohan C. Development of drugs based on bioactive heterocycles. *Med Chem Res*. 2016;25:173-210.
- [16]. Lee YT, et al. Benzimidazole and its derivatives as cancer therapeutics. *Acta Pharm Sin B*. 2023;13:478-97.
- [17]. Kumar M, et al. Benzimidazole-based therapeutics: A comprehensive review. 2024.
- [18]. Ferreira LG, et al. Molecular docking and structure-based drug design strategies. *Molecules*. 2015;20:13384-421.
- [19]. Matysiak J, et al. Biological Evaluation of 2-(2, 4-Dihydroxyphenyl)-1 H-Benzimidazole Analogues. *Biomolecules*. 2019;9:870.
- [20]. Pizzino G, et al. Oxidative stress: harms and benefits for human health. *Oxid Med Cell Longev*. 2017.
- [21]. Qin Y, et al. Oxidative Stress: Molecular Mechanisms and Therapeutic Targets. *MedComm*. 2026;7:e70600.
- [22]. Gulcin I, Alwasel SH. DPPH radical scavenging assay. *Processes*. 2023;11:2248.
- [23]. Mavrova AT, et al. Synthesis and antioxidant activity of new benzimidazoles. *Bioorg Med Chem*. 2015;23:6317-26.
- [24]. Satija G, et al. Benzimidazole based derivatives as anticancer agents: SAR analysis. *J Heterocycl Chem*. 2022;59:22-66.
- [25]. Daoud NE-H, et al. ADMET profiling in drug discovery and development. *Curr Drug Metab*. 2021;22:503-22.
- [26]. Thapa P, et al. 1, 2-Disubstituted benzimidazoles by iron catalyzed coupling. *J Org Chem*. 2020;85:1991-2009.
- [27]. Ibrahim AA, et al. Synthesis and SARs of benzimidazoles: insights into innovation. *RSC Adv*. 2025;15:22097-127.
- [28]. Basaran R, Kilcigil G. Evaluation of Antioxidant Activity of Imines Containing Benzimidazoles. *Turk J Pharm Sci*. 2020;17:626.
- [29]. Aroua LM, et al. Synthesis and bioactivity of hybrid benzimidazole urea derivatives. *Pharmaceutics*. 2023;15:457.
- [30]. Bano S, et al. Synthesis and anti-inflammatory activity of benzimidazole derivatives. *Heliyon*. 2024;10:e2900